|
1
|
Clauss M, Weich H, Breier G, Knies U,
Röckl W, Waltenberger J and Risau W: The vascular endothelial
growth factor receptor Flt-1 mediates biological activities.
Implications for a functional role of placenta growth factor in
monocyte activation and chemotaxis. J Biol Chem. 271:17629–17634.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim KJ, Cho CS and Kim WU: Role of
placenta growth factor in cancer and inflammation. Exp Mol Med.
44:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ding Y, Huang Y, Song N, Gao X, Yuan S,
Wang X, Cai H, Fu Y and Luo Y: NFAT1 mediates placental growth
factor-induced myelomonocytic cell recruitment via the induction of
TNF-alpha. J Immunol. 184:2593–2601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kerber M, Reiss Y, Wickersheim A, Jugold
M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M,
Plate KH and Machein MR: Flt-1 signaling in macrophages promotes
glioma growth in vivo. Cancer Res. 68:7342–7351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laurent J, Hull EF, Touvrey C, Kuonen F,
Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, et
al: Proangiogenic factor PlGF programs CD11b+
myelomonocytes in breast cancer during differentiation of their
hematopoietic progenitors. Cancer Res. 71:3781–3791. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Czepluch FS, Olieslagers S, van Hulten R,
Vöö SA and Waltenberger J: VEGF-A-induced chemotaxis of CD16+
monocytes is decreased secondary to lower VEGFR-1 expression.
Atherosclerosis. 215:331–338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin YL, Liang YC and Chiang BL: Placental
growth factor down-regulates type 1 T helper immune response by
modulating the function of dendritic cells. J Leukoc Biol.
82:1473–1480. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou X and Qi Y: Larynx carcinoma
regulates tumor-associated macrophages through PLGF signaling. Sci
Rep. 5:100712015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Selvaraj SK, Giri RK, Perelman N, Johnson
C, Malik P and Kalra VK: Mechanism of monocyte activation and
expression of proinflammatory cytochemokines by placenta growth
factor. Blood. 102:1515–1524. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pagani E, Ruffini F, Cappellini Antonini
GC, Scoppola A, Fortes C, Marchetti P, Graziani G, D'Atri S and
Lacal PM: Placenta growth factor and neuropilin-1 collaborate in
promoting melanoma aggressiveness. Int J Oncol. 48:1581–1589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graziani G, Ruffini F, Tentori L, Scimeca
M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S and
Lacal PM: Antitumor activity of a novel anti-vascular endothelial
growth factor receptor-1 monoclonal antibody that does not
interfere with ligand binding. Oncotarget. 7:72868–72885. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Atzori MG, Tentori L, Ruffini F, Ceci C,
Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, et
al: The anti-vascular endothelial growth factor receptor-1
monoclonal antibody D16F7 inhibits invasiveness of human
glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res.
36:1062017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atzori MG, Tentori L, Ruffini F, Ceci C,
Bonanno E, Scimeca M, Lacal PM and Graziani G: The anti-vascular
endothelial growth factor receptor-1 monoclonal antibody D16F7
inhibits glioma growth and angiogenesis in vivo. J Pharmacol Exp
Ther. 364:77–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berger NA, Besson VC, Boulares AH, Bürkle
A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson
VL, et al: Opportunities for the repurposing of PARP inhibitors for
the therapy of non-oncological diseases. Br J Pharmacol.
175:192–222. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martin-Hernandez K, Rodriguez-Vargas JM,
Schreiber V and Dantzer F: Expanding functions of ADP-ribosylation
in the maintenance of genome integrity. Semin Cell Dev Biol.
63:92–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai P and Virág L: Role of
poly(ADP-ribose) polymerases in the regulation of inflammatory
processes. FEBS Lett. 586:3771–3777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rom S, Zuluaga-Ramirez V, Reichenbach NL,
Dykstra H, Gajghate S, Pacher P and Persidsky Y: PARP inhibition in
leukocytes diminishes inflammation via effects on
integrins/cytoskeleton and protects the blood-brain barrier. J
Neuroinflammation. 13:2542016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shah GM, Robu M, Purohit NK, Rajawat J,
Tentori L and Graziani G: PARP inhibitors in cancer therapy: Magic
bullets but moving targets. Front Oncol. 3:2792013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pujade-Lauraine E, Ledermann JA, Selle F,
Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A,
Pignata S, et al: Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind,
randomised, placebo-controlled, phase 3 trial. Lancet Oncol.
18:1274–1284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a Germline
BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faraoni I, Compagnone M, Lavorgna S,
Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S,
Venditti A, et al: BRCA1, PARP1 and γH2AX in acute myeloid
leukemia: Role as biomarkers of response to the PARP inhibitor
olaparib. Biochim Biophys Acta. 1852:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ruffini F, Failla CM, Orecchia A, Bani MR,
Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S,
et al: Expression of the soluble vascular endothelial growth factor
receptor-1 in cutaneous melanoma: Role in tumour progression. Br J
Dermatol. 164:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lacal PM, Morea V, Ruffini F, Orecchia A,
Dorio AS, Failla CM, Soro S, Tentori L, Zambruno G, Graziani G, et
al: Inhibition of endothelial cell migration and angiogenesis by a
vascular endothelial growth factor receptor-1 derived peptide. Eur
J Cancer. 44:1914–1921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levati L, Ruffini F, Muzi A, Umezawa K,
Graziani G, D'Atri S and Lacal PM: Placenta growth factor induces
melanoma resistance to temozolomide through a mechanism that
involves the activation of the transcription factor NF-κB. Int J
Oncol. 38:241–247. 2011.PubMed/NCBI
|
|
25
|
White ES, Livant DL, Markwart S and
Arenberg DA: Monocyte-fibronectin interactions, via alpha(5)beta(1)
integrin, induce expression of CXC chemokine-dependent angiogenic
activity. J Immunol. 167:5362–5366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dewerchin M and Carmeliet P: Placental
growth factor in cancer. Expert Opin Ther Targets. 18:1339–1354.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jain RK, Duda DG, Willett CG, Sahani DV,
Zhu AX, Loeffler JS, Batchelor TT and Sorensen AG: Biomarkers of
response and resistance to antiangiogenic therapy. Nat Rev Clin
Oncol. 6:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bagley RG, Ren Y, Weber W, Yao M,
Kurtzberg L, Pinckney J, Bangari D, Nguyen C, Brondyk W, Kaplan J
and Teicher BA: Placental growth factor upregulation is a host
response to antiangiogenic therapy. Clin Cancer Res. 17:976–988.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fischer C, Jonckx B, Mazzone M, Zacchigna
S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M,
De Mol M, et al: Anti-PlGF inhibits growth of
VEGF(R)-inhibitor-resistant tumors without affecting healthy
vessels. Cell. 131:463–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Coenegrachts L, Maes C, Torrekens S, Van
Looveren R, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet
P and Carmeliet G: Anti-placental growth factor reduces bone
metastasis by blocking tumor cell engraftment and osteoclast
differentiation. Cancer Res. 70:6537–6547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei SC, Tsao PN, Weng MT, Cao Z and Wong
JM: Flt-1 in colorectal cancer cells is required for the tumor
invasive effect of placental growth factor through a p38-MMP9
pathway. J Biomed Sci. 20:392013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao J, Wu X, Zhuang G, Kasman IM, Vogt T,
Phan V, Shibuya M, Ferrara N and Bais C: Expression of a functional
VEGFR-1 in tumor cells is a major determinant of anti-PlGF
antibodies efficacy. Proc Natl Acad Sci USA. 108:11590–11595. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rolny C, Mazzone M, Tugues S, Laoui D,
Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et
al: HRG inhibits tumor growth and metastasis by inducing macrophage
polarization and vessel normalization through downregulation of
PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galdiero MR, Garlanda C, Jaillon S, Marone
G and Mantovani A: Tumor associated macrophages and neutrophils in
tumor progression. J Cell Physiol. 228:1404–1412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from
BRCA mutation carriers. N Engl J Med. 361:123–134. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roth J, Peer CJ, Mannargudi B, Swaisland
H, Lee JM, Kohn EC and Figg WD: A sensitive and robust ultra HPLC
assay with tandem mass spectrometric detection for the quantitation
of the PARP inhibitor olaparib (AZD2281) in Human plasma for
pharmacokinetic application. Chromatography. 1:82–95. 2014.
View Article : Google Scholar
|
|
38
|
Plummer R, Swaisland H, Leunen K, van
Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P,
Mau-Sørensen M, Nielsen D, et al: Olaparib tablet formulation:
Effect of food on the pharmacokinetics after oral dosing in
patients with advanced solid tumours. Cancer Chemother Pharmacol.
76:723–729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Askari JA, Buckley PA, Mould AP and
Humphries MJ: Linking integrin conformation to function. J Cell
Sci. 122:165–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ferreira AM, Isaacs H, Hayflick JS, Rogers
KA and Sandig M: The p110delta isoform of PI3K differentially
regulates beta1 and beta2 integrin-mediated monocyte adhesion and
spreading and modulates diapedesis. Microcirculation. 13:439–456.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tchaikovski V, Fellbrich G and
Waltenberger J: The molecular basis of VEGFR-1 signal transduction
pathways in primary human monocytes. Arterioscler Thromb Vasc Biol.
28:322–328. 2008. View Article : Google Scholar : PubMed/NCBI
|
